Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-NOTA-SNA002 PET/CT in Solid Tumors
NCT05490264Phase 1Recruiting
- Sponsor
- SmartNuclide
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium Ga-68 NOTA-SNA002 in solid tumor, sponsored by SmartNuclide. Primary endpoints: Incidence of adverse events, Changes of vital signs at Day 2 and 3 more. Started Oct 2022; status: recruiting.
02
Drugs
gallium Ga-68 NOTA-SNA002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05490264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490264.